2024 has seen a slew of mergers and acquisitions. Here's a breakdown of 10 major deals within the pharmaceutical and biotechnology sectors that have already taken place this year. This list highlights the ongoing trend of consolidation within the industry: 👇
Mirati Therapeutics
Acquired By: Bristol-Myers Squibb
Acquisition Date: Jan. 23, 2024
Acquisition Price: $4.8B
ImmunoGen
Acquired By: AbbVie
Acquisition Date: Feb. 12, 2024
Acquisition Price: $10.1B
Aiolos Bio
Acquired By: GlaxoSmithKline (GSK)
Acquisition Date: Feb. 15, 2024
Acquisition Price: $1B
Icosavax
Acquired By: AstraZeneca (AZN)
Acquisition Date: Feb. 19, 2024
Acquisition Price: $1.1B
Gracell Biotechnologies
Acquired By: AstraZeneca (AZN)
Acquisition Date: Feb. 22, 2024
Acquisition Price: $1.2B
RayzeBio
Acquired By: Bristol-Myers Squibb
Acquisition Date: Feb. 26, 2024
Acquisition Price: $4.1B
Ambrx Biopharma
Acquired By: Johnson & Johnson
Acquisition Date: Mar. 7, 2024
Acquisition Price: $2B
Harpoon Therapeutics
Acquired By: Merck
Acquisition Date: Mar. 11, 2024
Acquisition Price: $680M
Karuna Therapeutics
Acquired By: Bristol-Myers Squibb
Acquisition Date: Mar. 18, 2024
Acquisition Price: $14B
CymaBay Therapeutics
Acquired By: Gilead Sciences
Acquisition Date: Mar. 22, 2024
Acquisition Price: $4.3B
---
Get a list of all recently funded companies with deeper info to help your sales/BD activities. Contact us to learn more
Article History:
RF (04/02/24)
Comments